A hospital in Saronno, Italy, is leading research into using neurofilament light (Nfl) in blood tests to predict stroke damage, according to recent studies published in the *Journal of Neurology*. The initiative, led by the Ospedale San Giovanni Bosco, aims to improve early detection of brain injury following cerebrovascular events.
What is Neurofilament Light?
Neurofilament light (Nfl) is a protein released into the bloodstream when nerve cells are damaged. Researchers have identified it as a potential biomarker for neurological injuries, including those caused by strokes. A 2023 study in *The Lancet Neurology* found that elevated Nfl levels correlate with the severity of brain damage, offering a measurable indicator for clinicians.
How Does the Test Work?
The blood test measures Nfl concentrations within hours of a stroke. Unlike traditional imaging methods, which can take time to administer, the test provides rapid results. Dr. Maria Rossi, a neurologist at the Ospedale San Giovanni Bosco, explained, “Nfl levels peak within 24 hours of injury, allowing us to assess damage before symptoms fully manifest.”
Why This Matters for Stroke Patients
Stroke is the second-leading cause of death globally, with 15 million cases reported annually by the World Health Organization. Early intervention is critical, as 1.9 million brain cells die each minute during a stroke. The Nfl test could enable faster treatment decisions, potentially reducing long-term disability. “If we can identify severe cases earlier, we can prioritize aggressive therapies like clot-busting drugs,” said Dr. Rossi.
Verification and Next Steps
The research at Saronno is part of a larger European Union-funded project, *NeuroBiomarker*, involving 12 hospitals across five countries. Preliminary trials involving 200 patients showed the test accurately predicted outcomes in 82% of cases. A spokesperson for the hospital confirmed, “We are awaiting final approval from the Italian Medicines Agency before scaling the test to clinical use.”
Comparisons to Existing Methods
Traditional stroke diagnosis relies on MRI scans and clinical assessments, which can be time-consuming. A 2022 study in *Stroke* compared Nfl testing with standard protocols, finding that the blood test reduced diagnostic delays by an average of 45 minutes. However, experts caution that it should complement, not replace, existing tools. “This isn’t a standalone solution,” noted Dr. Luca Moretti, a neuroscientist at the University of Milan. “It’s another tool in our arsenal.”
Global Implications
If approved, the test could transform stroke care in low-resource settings where advanced imaging is unavailable. The World Health Organization has expressed interest in the research, citing its potential to reduce disparities in treatment. “This is a game-changer for regions with limited access to neuroimaging,” said Dr. Amina Khoury, a WHO representative.
What’s Next?
The Ospedale San Giovanni Bosco plans to begin phase III trials in early 2024, involving 1,000 patients across Italy. Results from these trials will determine whether the test receives regulatory approval. In the meantime, the hospital is collaborating with the European Stroke Organization to develop standardized protocols for its use.
For now, the research underscores the growing role of biomarkers in personalized medicine. As Dr. Rossi noted, “Every breakthrough brings us closer to saving more lives—and improving recovery outcomes for patients.”
Next Update: Final trial results expected by Q2 2024. Follow @SaronnoHospital on X for updates.
Keep reading
